dc.contributor.author | Dwivedi, Anupma | |
dc.contributor.author | Mazumder, Anisha | |
dc.contributor.author | Fox, Lizelle T. | |
dc.contributor.author | Brümmer, Alicia | |
dc.contributor.author | Gerber, Minja | |
dc.contributor.author | Du Preez, Jan L. | |
dc.contributor.author | Haynes, Richard K. | |
dc.contributor.author | Du Plessis, Jeanetta | |
dc.date.accessioned | 2016-03-30T12:51:20Z | |
dc.date.available | 2016-03-30T12:51:20Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Dwivedi, A. et al. 2016. In vitro skin permeation of artemisone and its nano-vesicular formulations. International journal of pharmaceutics, 503(1-2): 1-7. [https://doi.org/10.1016/j.ijpharm.2016.02.041] | en_US |
dc.identifier.issn | 0378-5173 | |
dc.identifier.issn | 1873-3476 (Online) | |
dc.identifier.uri | http://hdl.handle.net/10394/16743 | |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0378517316301466 | |
dc.identifier.uri | https://doi.org/10.1016/j.ijpharm.2016.02.041 | |
dc.description.abstract | The artemisinin derivative artemisone has antitumor activity. In particular when encapsulated in solid
lipid nanoparticles (SLNs) and niosomes, it is active against human melanoma A-375 cells, although such
formulations have a negligible effect on human keratinocyte cells. The aim here was to determine
whether these formulations could enhance the topical delivery and skin permeation of artemisone as a
prelude to evaluating use of artemisone and related compounds for melanoma treatment. In vitro skin
permeation studies were conducted to determine the concentration of artemisone delivered into the
stratum corneum-epidermis and epidermis-dermis. Artemisone-SLNs delivered artemisone into the
stratum corneum-epidermis at significantly higher concentration (62.632 mg/mL) than the artemisoneniosomes
(12.792 mg/mL). Neither of the controls delivered artemisone into the stratum corneumepidermis.
In the epidermis-dermis, artemisone (13.404 mg/mL) was only detected after application of
the SLN formulation. Overall, the excellent topical delivery of artemisone with the SLN formulation
coupled with the intrinsic activity of formulated artemisone confirms potential for use in treatment of
melanoma | en_US |
dc.description.sponsorship | South African National Research Foundation (NRF) (Grant Nos.
IFRR81178 and CPRR13091742482), the South African Medical
Research Council (MRC) for the Flagship Project MALTB-Redox, and
the Centre of Excellence for Pharmaceutical Sciences (Pharmacen)
of the North-West University, Potchefstroom Campus, South Africa | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.subject | Artemisone | en_US |
dc.subject | Melanoma | en_US |
dc.subject | Nano-vesicles | en_US |
dc.subject | Solid lipid nanoparticles | en_US |
dc.subject | Niosomes | en_US |
dc.subject | Skin permeation | en_US |
dc.title | In vitro skin permeation of artemisone and its nano-vesicular formulations | en_US |
dc.type | Article | en_US |
dc.contributor.researchID | 21205477 - Brümmer, Alicia | |
dc.contributor.researchID | 11329025 - Gerber, Minja | |
dc.contributor.researchID | 10060510 - Du Preez, Jan Lourens | |
dc.contributor.researchID | 22966390 - Haynes, Richard Kingston | |
dc.contributor.researchID | 10065318 - Du Plessis, Jeanetta | |
dc.contributor.researchID | 25224735 - Dwivedi, Anupma | |
dc.contributor.researchID | 25224786 - Mazumder, Anisha | |
dc.contributor.researchID | 12815268 - Fox, Lizelle Trifena | |